BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Oriel Therapeutics Inc., Awarded Its First U.S. Patent


10/19/2005 5:10:23 PM

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--May 10, 2005--Oriel Therapeutics Inc., an emerging inhaled drug delivery company based in Research Triangle Park, announced today that it has been granted a United States Patent (6,889,690; issue date May 10th) for multi-dose dry powder drug packages for holding pharmaceutical grade formulations of inhalable dry powder substances. The patent covers aspects of Oriel's multi-dose dry powder inhaler technology that provides a package to apply vibration directly to a powder drug as well as a design for delivery of drugs. The package can be configured to deliver drugs in combination without blending (i.e. in separate blisters). The vibration is individually tailored for a given drug product through use of powder physics principles and provides highly efficient dose delivery. Oriel's design enables increased formulation flexibility in the development of combination products. This coupled with the powder delivery technology will allow for more rapid product development and improved patient administration.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES